MLTX - Swiss biotech MoonLake begins dosing in mid-stage study of sonelokimab for skin disorder

Switzerland-based MoonLake Immunotherapeutics (NASDAQ:MLTX) said the first patient was dosed at a U.S. site of its global phase 2 trial of investigational Nanobody sonelokimab to treat patients with moderate-to-severe hidradenitis suppurativa (HS). HS is a condition causing small, painful lumps to form under the skin, in areas such as the armpits and groin. MoonLake, which went public recently via a merger with SPAC Helix Acquisition, said the study called MIRA evaluate the efficacy and safety of different doses of sonelokimab, compared with placebo, with adalimumab , sold as Humira by AbbVie, as an active control reference arm, in over 200 patients with HS. The trial's main goal is ?75% reduction in total abscess (pus) and inflammatory nodule. The study is expected to be completed by the end of 2023.

For further details see:

Swiss biotech MoonLake begins dosing in mid-stage study of sonelokimab for skin disorder